India, Oct. 11 -- What are the key highlights for the company in 2026?

For Kilitch Drugs, 2026 has been a year of continued growth, capacity expansion and portfolio diversification. The company recorded consolidated revenue from operations of Rs 235.47 crore in FY2025-26, compared with Rs 198.32 crore in the previous year. In Q1 FY2026-27, standalone revenue from operations stood at Rs 40.91 crore, with a PAT of Rs 5.05 crore.

A key development has been the commencement of the Nutraceutical Manufacturing Block at the Khopoli facility in Maharashtra. The expansion is expected to strengthen capacity across nutraceuticals, injectables, ophthalmics and cartridges filling line for Semaglutide filling, while supporting domestic and internatio...